SCHEMBL16337404

SCHEMBL16337404

Cc1cc(OCc2ccccc2)ccc1-c1c(C)c(=O)n(COCC[Si](C)(C)C)c(=O)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.41
MAOB P27338 8/20 0.40
MAOA P21397 4/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
PKM P14618 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ACHE P22303 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
GRM5 P41594 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16337126 0.90 PKM (0.40) DGAT1MAOBMAOANPC1RAB9A
SCHEMBL16334726 0.90 TNFRSF1A (0.40) DGAT1MAOBMAOANPC1RAB9A
SCHEMBL20610856 0.86 CRHR1 (0.38) DGAT1NPC1PIK3CAPRKDC
SCHEMBL16337243 0.83 NPC1 (0.37) NPC1
SCHEMBL22402289 0.82 NPC1 (0.36) DGAT1NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL16334441 0.82 SMN1; SMN2 (0.37) MAOBMAOANPC1RAB9APKM
SCHEMBL16363024 0.82 KDM4E (0.35) NPC1ALDH1A1HPGD
SCHEMBL16336781 0.82 DRD1 (0.35) DGAT1NPC1
SCHEMBL20858944 0.81 PKM (0.40) MAOBMAOANPC1RAB9APKM
SCHEMBL30864167 0.81 NPC1 (0.35) NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-09-10 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 DGAT1 761/4885MAOB 146/4885MAOA 189/4885
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 DGAT1 1119/4885MAOB 78/4885MAOA 64/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D DGAT1 1331/4885MAOB 139/4885MAOA 177/4885
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DGAT1 1331/4885MAOB 139/4885MAOA 177/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DGAT1 1331/4885MAOB 139/4885MAOA 177/4885
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 DGAT1 1119/4885MAOB 78/4885MAOA 64/4885
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DGAT1 1331/4885MAOB 139/4885MAOA 177/4885
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, SNCA DGAT1 1179/4885MAOB 96/4885MAOA 66/4885
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, SNCA DGAT1 1179/4885MAOB 96/4885MAOA 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.